Research news

Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options

February 2022

Design and basic characteristics of a national patient-powered registry in ADPKD

May 2022

Health Disparities in ADPKD in the United States

June 2022

Changing Health Disparities in ADPKD: a patient perspective

June 2022

Comparison of a pooled tolvaptan cohort to a pooled control cohort with ADPKD supports longer-term treatment effects of tolvaptan

May 2022

Insights into a tethered agonist-mediated activation mechanism of PC1 CTF signaling – how they inform future rational drug design targeting PC1

May 2022

Diagnosis and risk factors for intracranial aneurysms in ADPKD: a cross-sectional study from the Genkyst cohort

February 2022

Asymptomatic pyuria as a prognostic biomarker: associated with kidney failure and faster kidney function decline irrespective of the ADPKD gene, cystic burden, and cystic growth

March 2022

Kidney epithelial cells are active mechano-biological fluid pumps

April 2022

A single cell transcriptomic and epigenomic landscape of ADPKD

December 2021

A special issue on Cell Signaling in PKD, led by Drs. Albert C.M. Ong and Vicente E. Torres, and consisting of 30 papers from many respected members of the PKD research community.

July 2020

Cellular signaling in PKD foreword: dedicated to the memory of Dr. Jared James Grantham (1936–2016); without his vision, achievements and impact on countless collaborators and disciples, the field of Polycystic Kidney Disease would not be where it is today.

A study demonstrates the therapeutic feasibility of caloric restriction in ADPKD, with potential efficacy benefits driven by weight loss

January 2022

 

Linking a ciliary structural protein to the ADPKD spectrum – PKD1 variants could modify the IFT140 phenotype.

January 2022

Immune Cell Atlas Reveals the Involvement of Adaptive Immune Cells in Injury-Mediated Cyst Progression in Mice

February 2022

Insights Into the Molecular Mechanisms of Polycystic Kidney Diseases

September 2021

A Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD

April 2021

A substantial proportion of adolescents with ADPKD experience physical, social, and emotional impacts from their disease

January 2022

An updated algorithm to guide patient selection for treatment with tolvaptan and practical advice for its use

November 2021

Selective targeting of cyst cell proliferation is an effective means of slowing ADPKD progression caused by inactivation of Pkd1

November 2021

Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease

November 2021

The importance of local and systemic metabolism in ADPKD: current evidence for dietary interventions to slow disease progression and improve quality of life

November 2021

A possible association of a PKD2 mutation with an increased hazard of cardiac hospitalization as compared with PKD1

October 2021

Phenotypic features of ADPKD may be reversible -the kidney has an unexpected capacity for plasticity controlled at least in part by ADPKD gene function

October 2021

New insights into the normal function of PC2 as a ubiquitous stress-sensitive protein

January 2020

Results from the metformin feasibility study at University of Colorado Denver

August 2021

Inhibition of exosome biogenesis/release significantly delays cyst growth in aggressive and milder ADPKD mouse models

July 2021

A review summarizing current knowledge about the regulatory mechanism of ferroptosis and its association with several pathways, including iron, lipid, and cysteine metabolism

February 2021

Real-world utilization patterns of imaging scans in patients diagnosed with ADPKD

May 2021

Expanding the understanding of genotype-phenotype correlations in pediatric ARPKD

April 2021

Long-term treatment with tolvaptan gradually lowered blood pressure compared with placebo in clinical trials

April 2021

An analysis of the HALT-PKD data: pain and obesity in ADPKD

April 2021

Estimated total annual costs attributed to ADPKD estimated at $51,970 to $68,091 per patient

February 2020

Development of an ADPKD-specific pain assessment tool (APAT) to facilitate pain research

February 2021

Baseline urinary metabolic biomarkers associated with disease severity in TAME-PKD cohort

March 2021

A review assessing the risk of disease progression in ADPKD and identifying patients who would benefit from long-term therapy of disease-modifying agents

March 2021

A review of aspects of early manifestations in ARPKD and its clincial management with a special focus on kidney disease

February 2021

New conclusions on patients with protein-truncating PKD1 Mutations and mild disease

February 2021

A practical guide for the diagnostic and therapeutic management of an “acute abdominal pain with fever” in patients with ADPKD

February 2021

CDK7 as a novel therapeutic option: how super-enhancers play a critical role in ADPKD 

July 2020

Urine-to-plasma urea ratio, calculated from routine laboratory measurements, predicts disease progression in ADPKD

January 2021

A proof-of-concept for application of the combination of curcumin and ginkgolide B in inhibiting cystogenesis in ADPKD

January 2021

Using the Mayo Classification to evaluate the need for nephrectomy in ADPKD patients

December 2020

Predicting ADPKD outcomes using serum bicarbonate: a potential new prognostic model

December 2020

Refuting the hypothesis that Ca2+ occupancy of the polycytsin-2 intracellular EF hand is responsible for channel regulation, and if disrupted, results in ADPKD

October 2020

Cystogenesis and inflammation may be associated with endothelial dysfunction; ADPKD patients observed to have higher copeptin, NLRP3, and suPAR levels than controls

October 2020

Prospective observations of a cohort of 73 individuals with molecularly confirmed ARPKD-congenital hepatic fibrosis

September 2020

 A review of the advances and application of kidney organoids in regenerative medicine and as developmental, toxicity, and disease models

October 2020

Fibrocystin’s role in controlling STAT3 signalling in ARPKD

October 2020

Five novel GANAB variants found to be associated with PLD in both ADPKD and ADPLD patients

October 2020

Loss of Cdk1 significantly slows kidney cyst growth with Pkd1 inactivation 

October 2020

A focus group study on presymptomatic testing and decision-making challenges

October 2020

An editorial on sclerotherapy outcomes in ADPKD patients for treatment of pain  

October 2019

Hedgehod signaling and the role of fibrocystin in the abnormal vascular phenotype of PKD

October 2020

NIDDK Director, Robert Starr, discusses the promotion of innovative research in nephrology

August 2020

The role of excessive salt intake and vasopressin in promotion of cyst growth

October 2020

Laparoscopic bilateral nephrectomy at the time of kidney transplantation appears safe and feasible for ADPKD patients with living donors

September 2020

Development and validation of a fully automated approach for performing semantic segmentation of kidney cysts in MR images ADPKD patients

September 2020

New conclusions about PKHD1 and polycystic liver disease

September 2020

A new therapeutic concept using the FDA-approved drugs niclosamide and benzbromarone, and a TMEM16A-specific inhibitor in ADPKD mice

August 2020

Metabolic changes in PKD and their modulation as a potential target of systemic treatment

August 2020

SONG-PKD report on core outcomes sets for ADPKD trials

August 2020

A Patient Perspective on Genetic Testing for ADPKD

August 2020

Robotic ultrasound provides a rapid and accurate approach for noninvasively evaluating PKD in rodent models

August 2020

Measuring liver disease severity in ARPKD using magnetic resonance elastography

August 2020

The value of imaging, genotypic, and combined data to identify rapidly progressive ADPKD patients

August 2020

Qinzhe Wang, MS, PhD (University of Utah) awarded the Jared J. Grantham Research Fellowship

July 2020

Upregulated SEMA3C may contribute to survival of polycystic kidney epithelial cells

July 2020

Genetic reduction of cilium-length by targeting intraflagellar transport 88 protein impedes kidney and liver cysts formation

June 2020

Niacinamide well-tolerated in ADPKD patients, but no efficacy observed

June 2020

Genetic reduction of cilium length may offer novel therapeutic approaches for ADPKD

June 2020

Overview of in vivo and in vitro models for ADPKD

June 2020

More from HALT-PKD: KIM-1 and ADPKD progression

June 2020

MRI-based kidney T1 and T2 mapping as a non-invasive assessment of ARPKD progression

April 2020

An expanded imaging classification model for ADPKD

June 2020

A report on heathcare cost burden in ADPKD

April 2020

Identification of critically important consensus-based core outcome domains to be reported in trials

April 2020

Role of chemokines, innate and adaptive immunity in PKD

April 2020

A review of contributing factors of cardiovascular dysfunction in ADPKD

April 2020

The molecular impact of variants found in the TOP domain of polycystin-2

May 2020

Impaired mitochondrial structure and function play a role in PKD progression

April 2020

A review of outcomes reported in randomized trials conducted in patients with PKD

March 2020

Urinary exosomal miRNAs could serve as novel biomarkers of disease progression

March 2020

DNAJB11 mutations as described by atypical clinical presentations of ADPKD

March 2020

ADPKD’s economic burden is predominantly observed in direct health care costs

February 2020

National strategies needed to address racial and ethnic disparities in predialysis nephrology care

August 2020

Development of a high-throughput screening platform of cancer drugs in a quest to repurpose them for ADPKD

March 2020

Understanding the interplay between dysregulation of cellular metabolism and cystogenesis is likely to uncover pathways that can be directly modulated to treat PKD

September 2019

A review of ciliary dysfunction in cystic disease and the questions that remain

December 2019

A review and discussion of the therapeutic potential of metabolic reprogramming strategies in ADPKD

February 2020

Tubular secretion could be impaired in ADPKD independent of GFR

January 2020

Dietary phosphate restriction slows renal cyst growth and fibrosis in Pcy/pcy mouse model of PKD

January 2020

Patient engagement in research design improves feasibility, acceptability, rigor and relevance

March 2019

New mutation associated with ADPKD found on ALG9 gene

November 2019

Utilizing mosaicism to provide informed prognostic information and fully characterize ADPKD populations

February 2020

Cystic cells in PKD may be metabolically inflexible and could be exploited by dietary interventions or supplementation

December 2019

Meta-analysis demonstrates that GFR slope might be a viable surrogate endpoint in clinical trials for CKD

September 2019

 

FDA Removes Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326

December 2019

Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)

April 2019

FDA-approved cystic fibrosis drug, VX-809, may have potential utility for treating patients with ADPKD

December 2019

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan

October 2018

Ultrasound elastography is a useful noninvasive biomarker to detect and quantify liver fibrosis and portal hypertension in children with ARPKD

June 2019

PKD progression may be accelerated by commonly occurring renal crystal deposition that could be therapeutically controlled by relatively simple measures

July 2019

Metabolomics in ADPKD: how plasma metabolites and lipids are associated with kidney function and kidney volume in hypertensive patients

February 2019

A recent analysis on how race/ ethnicity affects progression and initiation of dialysis in ADPKD patients in the US

February 2019

How do cysts grow in ADPKD and how is it related to the gene?

June 2019

Get the latest information on treating PKD.

More information

For additional research information contact us!

Email: research@pkdcure.org
Phone: (800) 753-2873

Page last reviewed November 2022